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Abstract Altered fibrin clot structure has been reported
both in patients with coronary artery disease (CAD) and
those with type 2 diabetes mellitus (DM2). The aim of the
present study was to evaluate plasma fibrin clot perme-
ability and susceptibility to lysis in patients with DM2 and
CAD. We studied 132 consecutive CAD patients, including
67 subjects with DM2, scheduled for elective coronary
artery bypass grafting surgery. Ex vivo plasma fibrin clot
permeability (Ks) and lysis time (t50%) induced by 1 lg/mL
recombinant tissue plasminogen activator (tPA), along with
plasma levels of plasminogen activator inhibitor-1 (PAI-1),
thrombin activatable fibrinolysis inhibitor (TAFI), tPA, von
Willebrand factor (vWF), P-selectin, soluble CD40 ligand
(sCD40L), were measured. Diabetic and non-diabetic
patients did not differ in regard to demographics and
remaining cardiovascular risk factors. Concomitant DM2
was associated with higher glucose (?24.3 %, p \ 0.001),
fibrinogen (?9.0 %, p = 0.037), PAI-1 (?58.7 %,
p \ 0.001), tPA (?24.0 %, p \ 0.001) and P-selectin
(?12.2 %, p \ 0.001). Compared with the non-diabetic
group, the CAD patients with DM2 had lower Ks (-6.1 %,
p = 0.02) and prolonged t50% (?5.1 %, p = 0.04). Multi-
ple regression analysis of the whole study group showed
that vWF, PAI-1, fibrinogen and DM2 were the indepen-
dent predictors of t50% (R
2 = 0.58, p \ 0.001), while only
vWF was an independent predictor of Ks (R
2 = 0.22,
p \ 0.001). This study indicates that DM2 is potent enough
to unfavorably affect plasma fibrin clot characteristics
despite abnormal clot phenotype typically observed in
CAD. Of note, platelet and endothelial markers appear to
contribute to fibrin clot properties in CAD concomitant
with DM2.
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Introduction
Type 2 diabetes mellitus (DM2) is an independent risk
factor of coronary artery disease (CAD) and increases the
risk of CAD two to three times [1]. Up to 21.4 % of
patients with CAD has DM2 [2]. Moreover, the coexistence
of DM2 and CAD impairs cardiovascular prognosis and
increases the risk of ischemic events [3, 4]. This observa-
tion can be explained by several mechanisms, including
concomitant risk factors such as arterial hypertension,
obesity, and metabolic abnormalities such as hyperglyce-
mia, hyperinsulinemia, insulin resistance and dyslipidemia,
which are responsible for endothelial dysfunction [5]. It has
been demonstrated that atherosclerotic plaques in DM2
patients are more prone to rupture [6].
Both DM2 as well as CAD have been reported to
unfavorably affect structural and functional characteristics
of a fibrin clot relatively resistant to mechanical and
enzymatic degradation [7–9]. Fibrin clot structure and
functions depend on several genetic and environmental
factors present in both clinical entities, including enhanced
inflammatory status and oxidative stress [10]. Altered fibrin
clot architecture and function both in CAD and DM2 are
characterized by lower fibrin clot permeability resulting
from a smaller pore size in the fiber network, along with
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impaired susceptibility to lysis [7–12]. Specifically, the
altered fibrin structure in DM2 is largely attributed to
glycation of fibrinogen and fibrin [9], which may interfere
with fibrin polymerization, cross-linking by FXIII, tissue
plasminogen activator (tPA) and plasminogen binding and
plasminogen to plasmin conversion [8]. However, the data
on this association are not consistent [13]. Moreover,
fibrinogen is the main determinant of fibrin clot charac-
teristics and increased fibrinogen levels are commonly
observed in DM2. This abnormality results in formation of
more compact fibrin clots [13]. Hyperfibrinogenemia has
also been reported in several cohorts of CAD patients free
of DM2 and implicated in a higher risk of myocardial
infarction (MI) [14–16]. Importantly, there is evidence that
fibrin is a consistent component of atherosclerotic plaques,
and that the presence of fibrin can promote their growth,
being involved in the progression of atherosclerosis [17].
It is unclear whether DM2 is a modulator of fibrin clot
phenotype which is potent enough to alter the fibrin variables
modified already by a number of prothrombotic mechanisms
that operate in advanced CAD. It has been demonstrated that
acute hyperglycemia observed in up to 50 % of acute MI
patients could significantly reduce the efficiency of fibrino-
lysis but had no effect on clot permeability [9]. In advanced
atherosclerosis, the effect of DM2 on fibrin clot properties
appeared to be weaker and overruled by the impact of other
factors, including hyperhomocysteinemia and elevated
C-reactive protein [18]. Despite the fact that more tightly
packed and less porous fibrin structure has been observed
more often in CAD patients who experienced stent throm-
bosis in the past, the effect of DM2 on clot properties in this
population was negligible [19]. On the other hand, treatment
with insulin or biguanide has been shown to make fibrin more
permeable [20, 21]. Similarly, statin treatment can improve
fibrin clot characteristics in subjects with increased cardio-
vascular risk [9, 22].
The aim of this study was to evaluate the fibrin clot
permeability and susceptibility to lysis in CAD patients
with concomitant DM2 and determine factors that may
account for alterations in fibrin clot properties in such high-
risk population.
Methods
In this case–control study, we recruited 67 consecutive
white patients (44 males and 23 females) with CAD
(angiographically documented C70 % stenosis in at least
one epicardial coronary artery) and documented DM2,
scheduled for elective coronary artery bypass grafting
surgery (CABG). Diabetes was defined as a history of
diabetes regardless of disease duration, need for hypogly-
cemic agents, or fasting plasma glucose C126 mg/dL
(7 mmol/L) on two separate occasions. Exclusion criteria
were: cancer, acute illness, atrial fibrillation, liver injury,
acute coronary syndrome within the previous 6 weeks.
Medications were administered in unchanged doses for at
least 2 weeks before surgery. A control group comprised
65 non-diabetic CAD patients (49 males and 16 females),
scheduled for CABG at the same time and matched for age,
gender, and smoking habits. All patients signed an
informed consent. The study was approved by the Ethics
Committee of the Jagiellonian University.
All subjects calculated an individual body mass index
(BMI) using the standard formula: body mass in kilograms
divided by the square of height in meters.
Blood samples were drawn from an antecubital vein
with a minimal stasis prior to surgery. Lipid profile and
glucose was determined by routine laboratory methods.
Fibrinogen was determined using the von Clauss method.
High-sensitivity C-reactive protein (CRP) was measured by
nephelometry (Dade Behring). Commercially available
immunoenzymatic assays were used to determine fibrino-
lytic proteins, including plasma plasminogen activator
inhibitor-1 antigen (PAI-1; American Diagnostica, Stam-
ford, CT, USA), tPA (Diagnostica Stago, Asnieres,
France), thrombin activatable fibrinolysis inhibitor antigen
(TAFI; Chromogenix, Lexington, Massachusetts, United
States), von Willebrand factor (vWF; Diagnostica Stago,
Asnieres, France), and also platelet activation markers,
soluble CD40 ligand (sCD40L; R&D Systems, Indianap-
olis, IN, USA), and P-selectin (R&D Systems). All the
intra-assay and inter-assay coefficients of variation for the
ELISA measurements were below 7 %.
Fibrin clot permeability, expressed as a permeation
coefficient (Ks), which indicates the pore size, was deter-
mined as described [22]. Clot lysis time was determined
using a turbidity assay with slight modifications [22].
Briefly, citrated plasma was diluted with the Tris buffer,
containing 20 mmol/L CaCl2, 1 U/mL human thrombin
(Sigma) and 1 lg/mL recombinant tPA (Boerhinger
Ingelheim, Ingelheim, Germany). The time required for a
50 % decrease in clot turbidity (t50%) was determined [22].
All measurements were performed by technicians blinded
to the sample status. The coefficients of intra- and inter-
assay variations were 5–6 %.
Statistical analysis
The study was powered to have a 80 % chance of detecting a
5 % difference in plasma clot permeability and lysis time
using a p value of 0.05. In order to demonstrate such a dif-
ference or greater, 52 patients were required in each group.
For a p value of 0.01, 77 patients per group were required.
Continuous variables are expressed as mean ± SD or
median (interquartile range) and categorical variables as
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number (percentage). Continuous variables were checked
for normal distribution with Shapiro–Wilk test and com-
pared by Student’s t test or the Mann–Whitney U test as
appropriate. The Pearson or Spearman rank correlation
coefficients were calculated to test the association between
two variables with a normal or non-normal distribution,
respectively. The influence of different therapy of diabetes
on fibrin clot properties was checked with Kruskal–Wallis
ANOVA with multiple comparisons test. All clinical and
laboratory variables that showed the association with Ks or
t50% in univariate model (p B 0.2) and did not show sub-
stantial correlations (r [ 0.5) with another independent
variable were then included in the multiple linear regres-
sion analysis to determine predictors of Ks and t50% in the
study population. A p value \ 0.05 was considered statis-
tically significant.
Results
As shown in Table 1, diabetic and non-diabetic groups
were similar in terms of demographic variables and car-
diovascular risk factors except BMI, which was 9 % higher
in the former group (p \ 0.001). A larger proportion of
diabetic patients received angiotensin converting enzyme
inhibitors (ACEI; p = 0.001). Twenty-six patients in the
diabetic group received insulin alone, 27 were on oral
hypoglycemic drugs only, 7 received both insulin and oral
agents, while 7 patients were only on the diet.
As expected, diabetic patients had higher fasting glucose
(?24.3 %, p \ 0.001) and fibrinogen levels (?9.0 %,
p = 0.037). Elevated PAI-1 (?58.7, p \ 0.001), tPA
(?24.0 %, p \ 0.001) antigens, but not TAFI, were
observed in the diabetic group. Interestingly, P-selectin
was increased (?12.2 %, p \ 0.001) in the diabetic group.
vWF and sCD40L were similar in both groups (Table 2).
CAD patients with DM2 had different fibrin clot
parameters compared with the non-diabetic controls. Ks
was 6.1 % lower in the diabetic group (p = 0.02) while
t50% was 5.1 % longer in patients with DM2 (p = 0.04).
There were no significant differences in t50% between
patients receiving various hypoglycemic therapy
(p = 0.10) (Fig. 1). However, patients treated with oral
hypoglycemic drugs had 16.9 % lower Ks than those
treated with diet only (p \ 0.02) and subjects receiving
insulin had 14.6 % lower Ks than those on dietary treat-
ment only (p \ 0.09) (Fig. 1).
In diabetic group the inverse associations between Ks
and TAFI (r = -0.36, p = 0.003), PAI-1 (r = -0.38,
Table 1 Patient characteristics
Diabetic
subjects
n = 67
Controls
n = 65
p value
Age (years) 65.6 ± 7.8 65.3 ± 9.6 0.86
Male gender, n (%) 44 (66) 49 (75) 0.22
BMI (kg/m2) 29.6 ± 4.0 27.1 ± 3.8 0.002
Arterial hypertension, n (%) 61 (91) 54 (83) 0.17
Smoking, n (%) 17 (25) 14 (22) 0.60
Peripheral artery disease,
n (%)
6 (9) 13 (20) 0.07
Previous MI, n (%) 53 (79) 55 (87) 0.41
Aspirin, n (%) 11 (16) 10 (15) 0.87
Statins, n (%) 58 (87) 59 (91) 0.33
Fibrates, n (%) 1 (1) 0 0.32
Thienopyridine, n (%) 3 (4) 1 (2) 0.32
ACEI, n (%) 65 (97) 51 (78) 0.001
b-blocker, n (%) 61 (91) 58 (89) 0.73
Data are shown as mean ± SD or median (IQR) unless otherwise
indicated
BMI body mass index, MI myocardial infarction, ACEI angiotensin
converting enzyme inhibitor
Table 2 Laboratory investigations
Diabetic
subjects
n = 67
Control
subjects
n = 65
p value
Glucose (mmol/l) 6.8 (5.6–8.0) 5.3 (4.8–5.6) \0.001
Total cholesterol
(mmol/l)
4.91 (4.18–5.39) 4.53 (3.89–5.41) 0.40
Triglycerides
(mmol/l)
1.55 (1.21–1.96) 1.48 (1.10–1.79) 0.25
HDL cholesterol
(mmol/l)
1.24 (1.09–1.48) 1.31 (1.12–1.52) 0.29
LDL cholesterol
(mmol/l)
2.89 (2.42–3.64) 2.75 (2.32–3.57) 0.33
Platelets (9103/mm3) 213 (177–248) 219 (179–253) 0.69
Creatinine (lmol/L) 77 (43–172) 84 (43–154) 0.42
CRP (mg/l) 2.60 (1.65–4.41) 2.34 (1.64–4.33) 0.28
Fibrinogen (g/l) 4.43 (3.45–4.96) 3.87 (3.18–4.82) 0.037
PAI-1 (ng/ml) 65.4 (47.9–78.0) 27.0 (21.4–35.0) \0.001
TAFI (%) 103 (93–117) 106 (99–113) 0.76
tPA (ng/ml) 10.4 (9.0–11.1) 7.9 (6.5–9.9) \0.001
vWF (IU/ml) 108 (100–129) 108.0 (100–119) 0.31
sCD40L (ng/ml) 1.04 ± 0.24 0.97 ± 0.27 0.10
P-selectin (ng/ml) 199.4 ± 34.3 175.1 ± 39.8 \0.001
Ks (10
-9cm2) 7.70 ± 1.34 8.20 ± 0.92 0.02
t50% (min) 9.42 ± 1.47 8.94 ± 1.23 0.04
Data are shown as X ± SD or median (IQR)
HDL high-density lipoprotein, LDL low-density lipoprotein, CRP
C-reactive protein, PAI-1 plasminogen activator inhibitor-1, TAFI
thrombin activatable fibrinolysis inhibitor, tPA tissue plasminogen
activator, vWF von Willebrand factor, sCD40L soluble CD40 ligand,
Ks permeation coefficient, t50% clot lysis time
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p = 0.001), tPA (r = -0.27, p = 0.03) were observed
(Table 2). There were also negative correlations between
Ks and P-selectin (r = -0.40, p = 0.001; Fig. 3) and vWF
(r = -0.47, p \ 0.001; Fig. 2). Moreover, sCD40L and Ks
(r = -0.24, p = 0.06) tended to show inverse correlation
in the diabetic group. Similar correlations were not seen in
the non-diabetic CAD patients (data not shown).
In patients with DM2 but not in the non-diabetic group,
there was a positive correlation between t50% and CRP
(r = 0.31, p = 0.01). The positive associations t50% with
TAFI (r = 0.53, p \ 0.001) and tPA (r = 0.37, p = 0.002)
were demonstrated. In addition, PAI-1 had also positive
associations with Ks in diabetic (r = 0.57, p \ 0.001) and
non-diabetic patients (r = 0.62, p \ 0.001). In the both
groups, fibrinogen, P-selectin, vWF were positively corre-
lated with t50% (diabetic group (Fig. 3): r = 0.41, p \ 0.001;
r = 0.51, p \ 0.001; r = 0.71, p \ 0.001, respectively;
non-diabetic group: r = 0.52, p \ 0.001; r = 0.36,
p = 0.003; r = 0.49, p \ 0.001, respectively). Only in the
control group, sCD40L was correlated with t50% (r = 0.26,
p = 0.037).
A multiple linear regression analysis was performed to
determine the independent effect of laboratory and clinical
variables on Ks and t50%. Before the inclusion to the mul-
tiple model, significant correlations between independent
variables have been found. Ks was strongly correlated
with t50% (r = -0.67; p \ 0.001), vWF (r = -0.43;
p \ 0.001), PAI-1 (r = -0.37; p \ 0.001), and P-selectin
(r = -0.29; p = 0.001). t50% was significantly correlated
with vWF (r = 0.64; p \ 0.001), PAI-1 (r = 0.49;
p \ 0.001), P-selectin (r = 0.46; p \ 0.001), fibrinogen
(r = 0.46; p \ 0.001), TAFI (r = 0.39; p \ 0.001), and
CRP before CABG (r = 0.30; p \ 0.001). P-selectin was
correlated with PAI-1 (r = 0.47; p \ 0.001), and fibrinogen
(r = 0.29; p = 0.001) whereas PAI-1 with t-PA (r = 0.38;
p \ 0.001), and vWF (r = 0.44; p \ 0.001). Fibrinogen was
correlated with CRP (r = 0.53; p \ 0.001), platelet count
(r = 0.37; p \ 0.001), and vWF (r = 0.30; p \ 0.001).
Finally, the multivariate model for the whole study popula-
tion showed that vWF, PAI-1, fibrinogen and diabetes mel-
litus were the independent predictors of t50% (R
2 = 0.58,
p \ 0.001; Table 3) whereas vWF was the only independent
predictor of Ks (R
2 = 0.22, p \ 0.001; Table 3).
Discussion
The present study shows that DM2 is associated with
decreased clot permeability and susceptibility to lysis in
patients with severe CAD. A strong modulatory effect of
DM2 on plasma fibrin clot phenotype has been observed in
the presence of several factors leading also to the formation
of more dense and less lysable clots such as smoking,
hypertension and elevated CRP levels [10].
Fig. 1 Clot lysis time (t50%)
and permeation coefficient (Ks)
in relation to different therapy
of diabetes. Abbreviations: box
plot shows median and
interquartile range (IQR) (Q3 to
Q1). Q1 and Q3 are the first and
third quartiles. Whiskers are
drawn at Q3 ? 1.5 9 IQR,
Q1 - 1.5 9 IQR. Extreme
values are omitted
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Dunn et al. [8] have reported that the fibrin clots formed
from fibrinogen obtained from patients with DM2 had
denser, less porous structure than controls. That was related
to glycemic control but they had excluded CAD patients.
The lack of associations between both fibrin variables and
glycemia indicates that other factors may account for
alterations in fibrin clot phenotype in CAD patients.
Platelet activation is a well known modifier of fibrin clot
properties. It has been shown that altered clot properties
can be caused by a number of platelet-derived proteins
mainly released at the sites of platelet aggregation [23].
Polyphosphates secreted from dense granules can alter the
formation of fiber aggregates [24]. In the presence of
activated platelets, a fibrin clot may have a different
architecture with local increase in fiber density [25].
Moreover, it has been demonstrated that the use of anti-
platelet agents in patients with DM2 can overcome to some
extent the potential effects of poor glycemic control on
platelet reactivity [26]. Our study shows that P-selectin,
which is expressed in alpha-granules of activated platelets,
was increased in patients with DM2 and CAD compared
with non-diabetic subjects. Another platelet marker,
sCD40L, which did not differentiate diabetic and non-
Fig. 2 Correlation between permeation coefficient (Ks) and von
Willebrand factor (vWF) and P-selectin in diabetic patients
Fig. 3 Correlation between clot lysis time (t50%) and von Willebrand
factor (vWF) and P-selectin in diabetic patients
Table 3 Multiple linear regression with permeation coefficient or
lysis time as the dependent variable
Dependent
variable
Independent
variable
Contribution
of variance, %
p b
Ks vWF 10.5 \0.0001 -0.36
Diabetes mellitus 2.1 0.07 -0.15
TAFI 1.2 0.10 -0.13
ACEI 0.04 0.85 -0.02
CRP 0.01 0.95 -0.01
t50% vWF 16.4 \0.0001 0.43
PAI-1 16.3 \0.0001 0.45
Fibrinogen 5.5 0.0004 0.23
Diabetes mellitus 9.1 0.002 -0.30
ACEI 0.36 0.33 0.06
Abbreviations: see Tables 1 and 2
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diabetic CAD patients, showed weaker or no associations
with fibrin parameters in the current study. This provides
evidence for a role of platelet activation in altering the
fibrin clot structure in diabetic CAD patients.
An original finding is a strong association between vWF
and clot properties, both permeability and lysis, observed
in advanced CAD. Interestingly, in this patient group vWF
was a predictor of Ks, indicating novel associations linking
endothelial dysfunction with fibrin clot properties mea-
sured ex vivo. Endothelial dysfunction implies an alteration
in endothelial integrity and, as such, may be assessed by
flow-mediated dilatation or by changes in circulating
markers, such as plasma vWF [27]. It remains to be
established whether vWF per se might actively alter plasma
fibrin network properties.
TAFI combines fibrinolysis with coagulation cascade
[28]. There have been previous studies showing increased
[29–31] or decreased TAFI levels [32, 33] in CAD patients.
There have been, however, few reports evaluating the effect
of TAFI on clot lysis time in diabetic subjects that demon-
strated no effect [34] or hypofibrinolysis [35]. In the present
study, despite similar TAFI levels in both groups, we found
associations between permeability, lysis time and TAFI only
in the diabetic CAD group. The impact of TAFI on plasma
fibrin clot phenotype in DM2 merits further investigation.
Given the fact that in both groups, a significant per-
centage of CAD patients was taking statins, which have
been reported to increase the clot permeability and lysis
time [9, 22], it might be concluded that both drugs, though
they can improve clot phenotype, were not able to abolish a
complex effect of DM2 on fibrin variables [9, 11, 13]. Of
note, there were differences in clot permeability associated
with the mode of treatment of DM2. Taking into account
the previous findings [20, 21], this probably resulted from
disease severity and a specific effect of insulin or oral
antidiabetic agents.
In the present study, PAI-1, fibrinogen and DM2 have
been found to be the independent predictors of t50%, and
vWF both t50% and Ks. PAI-1 is protein mostly released
from the endothelium and from blood platelets. It is
responsible for impaired fibrin clot degradation in platelet-
rich plasma. It appears that coexistence of atherosclerosis
and DM2 might markedly enhance influence of the endo-
thelial cell and the platelet activation on t50%. This sur-
prising finding deserves further investigation.
Several limitations of our study warrant consideration.
First, the size of this study is limited. Nevertheless, diabetic
patients were matched with the non-diabetic group for most
parameters. Second, glycated hemoglobin HbA1c was not
determined. Third, imaging analysis using scanning elec-
tron microscopy was not performed. Nevertheless, sample
preparation including dehydratation hampers the extrapo-
lation of microscopic findings to the in vivo conditions.
In conclusion, our observations indicate that the DM2 is
potent enough to unfavorably affect the plasma fibrin clot
characteristics despite the altered clot phenotype as typi-
cally observed in advanced CAD. In this clinical study
platelet and endothelial markers appear to contribute to
fibrin clot properties in CAD concomitant with DM2.
Further studies are needed to determine the mechanism of
the altered fibrin clot structure formation in patients with
DM2 and advanced CAD.
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